Tag: Cancer: Prostate
Breast, Cervical, Prostate Cancer Screening Still Lower Than Before Pandemic
Prevalence of colorectal cancer screening remained unchanged with increase in stool testing offsetting decrease in colonoscopy
Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer
Longer duration of imaging-based progression-free survival seen in intent-to-treat population and those with BRCA mutation
Talazoparib + Enzalutamide Beneficial in Metastatic Prostate Cancer
Improvement seen in median imaging-based progression-free survival, regardless of homologous recombination repair status
Plant-Based Diet Linked to Reduced Risk for Prostate Cancer Progression
Men in highest quintile of plant-based dietary index had significantly lower risk for prostate cancer progression and recurrence
Patient-Reported Outcome Measure Developed for Radionuclide Therapy in Prostate Cancer
15-item measure deemed by key stakeholders to be relevant and useful in context of RNT for prostate cancer
Apalutamide Safe for Men With Prostate Cancer on Active Surveillance
Greater number of negative posttreatment biopsies seen among men with higher baseline genomic risk score
MRI-Guided Radiotherapy Bests CT Guidance for Prostate Cancer
Benefits seen for genitourinary and gastrointestinal toxic effects
Social Determinants of Health Affect Racial Disparity in Prostate Cancer Mortality
When accounting for social determinants of health, Black men have significantly lower prostate cancer-specific mortality than White men
Low-Value Prostate Cancer Screening Common in Primary Care
Providers who order several tests are more likely to order low-value prostate cancer screening
Per-Patient Costs of Metastatic Prostate Cancer Estimated at $31,427
Increase in annual attributable costs observed over time, from $28,311 in 2007-2013 to $37,055 in 2014-2017
